Trade C4 Therapeutics, Inc. - CCCC CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.03
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02226 %(-$2.23)Trade size with leverage ~ $10,000.00Money from leverage ~ $$9,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.00)Trade size with leverage ~ $10,000.00Money from leverage ~ $$9,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 10.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02226 %
  (-$2.23)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.00)

Key Stats

• Prev. Close: 2.76
• Open: 2.69
• 1-Year Change: 9.8%
• Day's Range: 2.69 - 2.83

Trade C4 Therapeutics, Inc. - CCCC

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.